CD86 and prostate adenocarcinoma: The current study found that the knockdown of EPHB1 or inhibition of GSK3B promoted the fluorescence intensity of CD86 but reduced that of CD206 in PRAD cells cocultured with macrophages, indicating that EPHB1 and GSK3B were key risk factors for promoting PRAD progression.